Stereotaxis, Inc.
Business
Stereotaxis designs, manufactures and markets robotic magnetic navigation (RMN) systems, instruments and information systems for interventional labs, enabling precise computer-controlled magnetic delivery of catheters for complex procedures. Primary products include the Genesis RMN and GenesisX RMN Systems, Odyssey/Synchrony/SynX Solutions, and disposable interventional devices (Map-iT, MAGiC, EMAGIN brands). The company focuses on electrophysiology cardiac ablation procedures for arrhythmias, with expansion into coronary, neuro and peripheral interventions through strategic partnerships with fluoroscopy manufacturers, catheter providers and mapping-system vendors globally.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 32 | 27 | 27 | 28 | 35 | |
| Total cost of revenue | 15 | 12 | 12 | 10 | 12 | |
| Gross margin | 17 | 15 | 15 | 18 | 23 | |
| Research and development | 9 | 10 | 10 | 11 | 10 | |
| Sales and marketing | 12 | 12 | 12 | 12 | 12 | |
| General and administrative | 18 | 17 | 14 | 14 | 14 | |
| Other | −492,000 | — | — | — | — | |
| Total operating expenses | 39 | 39 | 37 | 37 | 36 | |
| Operating loss | −22 | −25 | −22 | −19 | −13 | |
| Other income | 2,000 | — | 30,000 | — | — | |
| Interest income, net | 500,000 | 700,000 | 1 | 500,000 | −11,000 | |
| Net loss | −22 | −24 | −21 | −18 | −11 | |
| Cumulative dividend on convertible preferred stock | −1 | −1 | −1 | −1 | −1 | |
| Net loss attributable to common stockholders | −23 | −25 | −22 | −20 | −12 | |
| Basic (per share) | −0.25 | −0.3 | −0.27 | −0.26 | −0.16 | |
| Diluted (per share) | −0.25 | −0.3 | −0.27 | −0.26 | −0.16 | |
| Basic (shares) | 91 | 85 | 81 | 76 | 76 | |
| Diluted (shares) | 91 | 85 | 81 | 76 | 76 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 12 | 20 | 9 | 39 | |
| Restricted cash - current | — | 219,000 | 525,000 | 525,000 | 453,000 | |
| Accounts receivable, net of allowance of $541 and $582 at 2025 and 2024, respectively | 6 | 4 | 4 | 5 | 5 | |
| Insurance receivable | 4 | — | — | — | — | |
| Inventories, net | 10 | 8 | 8 | 8 | 4 | |
| Prepaid expenses and other current assets | 698,000 | 2 | 676,000 | 1 | 2 | |
| Total current assets | 34 | 26 | 33 | 43 | 51 | |
| Property and equipment, net | 3 | 4 | 3 | 4 | 3 | |
| Goodwill | 4 | 4 | — | — | — | |
| Intangible assets, net | 6 | 7 | — | — | — | |
| Operating lease right-of-use assets | 5 | 5 | 5 | 5 | 6 | |
| Prepaid and other non-current assets | 278,000 | 107,000 | 137,000 | 208,000 | 278,000 | |
| Total assets | 52 | 47 | 42 | 53 | 61 | |
| Accounts payable | 5 | 6 | 3 | 3 | 4 | |
| Accrued liabilities | 2 | 3 | 3 | 3 | 3 | |
| Accrued legal liabilities | 4 | — | — | — | — | |
| Deferred revenue | 6 | 7 | 7 | 7 | 6 | |
| Current contingent consideration | 5 | 6 | — | — | — | |
| Current portion of operating lease liabilities | 642,000 | 570,000 | 428,000 | 373,000 | 268,000 | |
| Total current liabilities | 22 | 22 | 13 | 14 | 13 | |
| Long-term deferred revenue | 555,000 | 2 | 2 | 2 | 2 | |
| Long term contingent consideration | 5 | 6 | — | — | — | |
| Operating lease liabilities | 5 | 5 | 5 | 5 | 6 | |
| Other liabilities | 1 | 64,000 | 43,000 | 51,000 | 218,000 | |
| Total liabilities | 34 | 35 | 20 | 21 | 22 | |
| Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized; 21,008 and 21,458 shares outstanding at 2025 and 2024, respectively | 5 | 5 | 6 | 6 | 6 | |
| Common stock, par value $0.001; 300,000,000 shares authorized, 95,339,628 and 85,326,557 shares issued at 2025 and 2024, respectively | 95,000 | 85,000 | 81,000 | 75,000 | 75,000 | |
| Additional paid in capital | 597 | 568 | 554 | 543 | 533 | |
| Treasury stock, 4,015 shares at 2025 and 2024 | −206,000 | −206,000 | −206,000 | −206,000 | −206,000 | |
| Accumulated deficit | −583 | −562 | −538 | −517 | −499 | |
| Total stockholders equity | 13 | 6 | 16 | 26 | 34 | |
| Total liabilities and stockholders equity | 52 | 47 | 42 | 53 | 61 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 626,000 | 587,000 | 595,000 | 429,000 | 106,000 | |
| Amortization of intangibles | 900,000 | 400,000 | — | — | — | |
| Loss on revaluation of contingent consideration | 2 | 2 | — | — | — | |
| Non-cash lease expense | 1,000 | 14,000 | — | — | 3 | |
| Stock-based compensation | 10 | 10 | 11 | 11 | 9 | |
| Accounts receivable | −2 | 691,000 | 1 | 316,000 | −2 | |
| Inventories | −1 | 677,000 | −550,000 | −3 | −1 | |
| Prepaid expenses and other current assets | 1 | −146,000 | 649,000 | 1 | −640,000 | |
| Other assets | −170,000 | 29,000 | 71,000 | 70,000 | 30,000 | |
| Accounts payable | −880,000 | 758,000 | 218,000 | −169,000 | 1 | |
| Accrued liabilities | 188,000 | −99,000 | −334,000 | −267,000 | −681,000 | |
| Deferred revenue | −3 | 574,000 | −702,000 | 989,000 | 3 | |
| Other liabilities | −13,000 | 21,000 | −8,000 | −167,000 | 87,000 | |
| Net cash used in operating activities | −14 | −8 | −9 | −8 | −3 | |
| Purchase of property and equipment | −93,000 | −34,000 | −366,000 | −2 | −1 | |
| Cash acquired in business acquisitions | — | 108,000 | — | — | — | |
| Net cash (used in) provided by investing activities | −93,000 | 74,000 | 20 | −22 | −1 | |
| Proceeds from issuance of stock | 16 | 297,000 | 81,000 | 220,000 | 547,000 | |
| Equity issuance costs | −893,000 | — | — | — | — | |
| Net cash provided by financing activities | 15 | 297,000 | 81,000 | 220,000 | 547,000 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 985,000 | −8 | 11 | −30 | −4 | |
| Fair value of shares of common stock issued for contingent consideration earnouts | 4 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Stereotaxis, Inc.'s CIK number?
Stereotaxis, Inc.'s SEC CIK number is 0001289340 (1289340). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Stereotaxis, Inc.'s SEC filings?
All of Stereotaxis, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Stereotaxis, Inc. last report earnings?
Stereotaxis, Inc. (STXS) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022488). This is Stereotaxis, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Stereotaxis, Inc.'s most recent earnings 8-K?
Stereotaxis, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001493152-26-022488. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Stereotaxis, Inc.'s latest earnings 8-K →
Look up any company's CIK number →